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The APP-processing pathway is a pathological component of Alzheimer’s disease (AD), but there is 
no consensus regarding the physiological functions of APP and its products. Two studies (Nikolaev 
et al., 2009; Lauren et al., 2009) link the physiological and pathological aspects of APP processing. 
They show that the APP products, N-APP and Aβ42, are ligands for death receptor 6 and cellular prion 
protein, respectively, which are important in nervous system development and synaptic suppression.It can be argued that pathology never exists for pathology’s 
sake—pathogenic mechanisms do not exist solely to induce dis-
ease. Instead, they are a reflection of aberrations in normal physi-
ological processes. This notion is beautifully underscored by two 
recent studies (Lauren et al., 2009; Nikolaev et al., 2009) that sug-
gest normal physiological functions for products of the amyloid 
precursor protein (APP) that may be involved in the pathogenesis 
of Alzheimer’s disease (AD).
AD is an age-dependent neurodegenerative disorder char-
acterized clinically by a relentless and progressive decline in 
cognitive ability, and pathologically by senile plaques, neu-
rofibrillary tangles, and neuronal loss in select brain regions. 
Although the etiology of AD remains unclear, the leading 
hypothesis is that accumulation of amyloid-β (Aβ) peptide, a 
product of APP processing, is the causative component of AD 
pathogenesis (Hardy and Selkoe, 2002; Price et al., 1998).But how is Aβ generated? The ectodomain of APP (sAPPα or 
sAPPβ) is released through cleavage by either α- or β-secretase, 
and the remaining transmembrane domain is then subjected to 
γ-secretase cleavage (reviewed in Hardy and Selkoe, 2002; Thi-
nakaran and Koo, 2008) (Figure 1). Although α-secretase cleav-
age generates products regarded as nontoxic or neurotrophic, 
β-secretase (mostly BACE1) initiates the amyloidogenic and 
pathogenic branch of APP processing. Further processing of 
the β-secretase cleavage product C-terminal APP (C-APP) by 
γ-secretase (for which presenilins 1 and 2 act as catalytic sub-
units), releases Aβ peptides of varying length from the plasma 
membrane, depending on the site of cleavage. Of these, Aβ42 
has an increased propensity to form the fibrillar amyloid aggre-
gates that are found in the brains of AD patients. Aβ42 is widely 
regarded as the main pathogenic species causing AD, unlike its 
more common but less fibrillogenic relative, Aβ40.Figure 1. APP Processing in Physiology and Pathology
(Left) APP is cleaved by α-secretase or β-secretase, and then by γ-secretase to produce various APP products, including N-terminal APP fragment (N-APP), amyloid-β 
peptide (Aβ), and APP intracellular domain (AICD). The various fragments perform distinct physiological functions: N-APP induces axonal pruning and neuronal cull-
ing by binding to DR6, and Aβ42 oligomers maintain synaptic homeostasis by binding to the prion protein (PrP). (Right) During AD pathogenesis, APP processing is 
increased or altered by genetic factors such as trisomy 21 in Down’s syndrome, mutations in APP, or putative sporadic mechanisms. The resulting increase in Aβ42 and 
N-APP impairs synaptic plasticity and induces aberrant neuronal and axonal degeneration in a temporal and/or spatial pattern that may be dependent on the expres-
sion of the receptors PrP and DR6. Red, genetic factors driving APP processing; blue, possible events inducing sporadic AD; PS1 and PS2, presenilin 1 and 2.Cell 137, June 12, 2009 ©2009 Elsevier Inc. 997
A role for APP processing in AD pathogenesis is supported by 
findings in patients with familial AD (FAD), a rare but highly aggres-
sive form of AD that is usually inherited in an autosomal dominant 
manner. All FAD cases identified thus far have mutations in the 
APP or presenilin genes resulting in increased β-secretase pro-
cessing and/or enhanced Aβ42 generation (Price et al., 1998). 
Individuals with Down’s syndrome, who have an extra copy of 
APP, develop dementia that appears to be clinically identical to 
AD (Price et al., 1998).
Although the pathological properties of Aβ42 and to a lesser 
extent other APP products (Aβ40, C-APP) are under intense inves-
tigation, there is no consensus about the specific mechanisms by 
which they exert these effects. Thus, insights into the physiological 
functions of APP products, such as identification of physiological 
interaction partners, may yield answers. Of the proposed physi-
ological functions for APP and its products (reviewed in Mattson, 
1997; Thinakaran and Koo, 2008), the best established is a role for 
sAPPα in promoting neuronal survival. Other reports link sAPPα 
to neurite outgrowth, full-length APP to neuronal migration, and 
the APP intracellular domain (AICD) to transcriptional modulation. 
Several proteins, including the receptor for advanced glycation 
end products (RAGE) and the α7 nicotinic acetylcholine recep-
tor, have been proposed to be receptors for Aβ42 (Verdier et al., 
2004). But most proposed physiological functions for APP prod-
ucts, especially neurotrophic functions, are unlikely to explain the 
pathology that occurs when APP processing is upregulated.
Two recent studies (Lauren et al., 2009; Nikolaev et al., 2009) 
now connect the physiological and pathological functions of APP-
processing products. Lauren et al. show that Aβ42 binds to the 
cellular prion protein (PrP), which itself can cause neuropathol-
ogy when misfolded. In a separate study, Nikolaev et al. report 
that the N-terminal fragment of APP (N-APP) interacts with death 
receptor 6 (DR6), resulting in pruning of axons and neurons dur-
ing development of the central nervous system (CNS).These stud-
ies suggest that APP processing constitutes a complex signaling 
center that serves multiple physiological functions that could trig-
ger pathological events when deregulated during disease.
Aβ42, Prion Protein, and Synaptic Suppression
Loss of synapses and synaptic activity is thought to underlie the 
progressive cognitive decline seen in AD. Transgenic mice over-
expressing APP carrying FAD mutations appear to successfully 
recapitulate this aspect of AD, exhibiting synaptic dysfunction and 
behavioral deficits (Price et al., 1998). Organotypic cultures from 
these mice display impairments in long-term potentiation (LTP), a 
measure of the strengthening of synaptic connections after elec-
trical stimulation that is the basis of learning and memory. Aggre-
gates of Aβ42 are postulated to be responsible for this effect, and 
nanomolar concentrations of Aβ42 oligomers can block LTP, trig-
ger synaptic retraction, and cause impairments in learning and 
memory in rodents (Hardy and Selkoe, 2002).
Direct mechanisms underlying the synaptotoxic (synaptic 
inhibitory) functions of Aβ42 aggregates have not been clearly 
demonstrated; there has been some speculation that Aβ42 aggre-
gates “gum up” synapses, that is, block synaptic function through 
obstruction. Now, Lauren et al. (2009) uncover a molecular basis 
for Aβ42’s antisynaptic function by identifying a specific receptor 
for oligomeric Aβ42 that mediates its effects on LTP suppression. 998 Cell 137, June 12, 2009 ©2009 Elsevier Inc.They devised an elegant screen based on the simple observa-
tion that Aβ42 oligomers bind to cultured hippocampal neurons 
with high affinity but not to COS-7 cells. This enabled them to 
screen a mouse brain complementary DNA (cDNA) library for 
genes that allow Aβ42 oligomers to bind to COS-7 cells. From 
225,000 clones, two positive clones were isolated, both encoding 
PrP. Aβ42 oligomers bind to PrP with high affinity and specificity. 
Aβ42 either did not bind to RAGE or the α7 nicotinic acetylcho-
line receptor or bound with very low affinity. Nanomolar concen-
trations of oligomeric Aβ42 potently inhibited LTP, but this effect 
could be abrogated either in the absence of PrP or by blocking 
the Aβ42-PrP interaction with antibodies against the Aβ42-binding 
region. Thus, the authors provide compelling evidence that PrP 
is a specific binding partner for Aβ42 oligomers and mediates 
Aβ42’s inhibitory effect on synaptic plasticity. This finding fits well 
with previous reports that independently implicate Aβ42 and PrP 
in synaptic function (Westergard et al., 2007). Thus, the Aβ42-PrP 
signaling pathway may be at play in the cognitive impairment of 
AD, and PrP may constitute a new therapeutic target. The high 
affinity and specificity of the Aβ42-PrP interaction suggests that 
rather than being a “random encounter” with pathological con-
sequences, this interaction and the subsequent suppression of 
synaptic activity may serve a physiological purpose. Indeed, the 
notion of a physiological function for Aβ42 in synaptic suppression 
has been suggested before. Induction of synaptic activity in orga-
notypic cultures enhances Aβ42 (and Aβ40) generation, which 
appears to act as a negative feedback loop in excitatory synaptic 
transmission (Kamenetz et al., 2003). Hinting at a physiological 
role for synaptic activity-driven negative feedback, mice lacking 
APP are more sensitive to seizures induced by the drug kainate. 
PrP may also play an inhibitory role in excitatory synaptic trans-
mission, and protects against excitotoxic damage in vivo (Khos-
ravani et al., 2008). Thus, the Aβ42-PrP interaction may serve a 
physiological purpose in maintaining synaptic homeostasis and in 
guarding against excessive excitation. The excess generation and 
extracellular accumulation of Aβ42 encountered in AD could lead 
to a pathological suppression of synaptic activity.
When considering either the physiological or pathological role 
of the Aβ42-PrP interaction, it will be necessary to obtain defini-
tive identification of the responsible Aβ42 oligomers, as well as 
their characterization and quantification in AD and non-AD brain 
tissue. Also, it is still undetermined whether the low levels of oligo-
meric Aβ42 in non-AD human or mouse brains would be sufficient 
to modulate PrP signaling. It is possible that even minute levels of 
oligomeric Aβ42 could trigger suppression of synaptic activity if 
concentrated within the synapse. Alternatively, Aβ42-PrP signal-
ing may be a safeguard mechanism that is only activated during 
heightened synaptic activity (and increased Aβ42) encountered, 
for example, during an epileptic seizure or excitotoxic event. Inter-
estingly, picomolar concentrations of Aβ42 can actually enhance 
LTP (Puzzo et al., 2008), further supporting a physiological role 
for Aβ42 in synaptic homeostasis, but indicating that our under-
standing of Aβ42′s role in synaptic plasticity is far from complete.
What are the downstream mechanisms by which the Aβ42-PrP 
interaction impairs LTP? Although PrP interacts with and inhibits 
NMDA receptor subunit 2D (Khosravani et al., 2008), Lauren et al. 
(2009) observed that this receptor is insensitive to Aβ42 oligom-
ers when expressed in frog oocytes. As this is a heterologous 
system, one cannot rule out that the Aβ42-PrP interaction may 
inhibit NMDA receptor subunit 2D or other glutamate receptors in 
the presence of neuron-specific components. Also, Lauren and 
coworkers found that PrP and its binding to Aβ42 oligomers is 
localized predominantly in dendrites and at postsynaptic termi-
nals. However, PrP also may be concentrated at presynaptic ter-
minals (Westergard et al., 2007), and thus both pre- and postsyn-
aptic mechanisms should be considered. One possibility is that 
Aβ42 may compete with synaptic proteins for binding to PrP.
Crossing PrP-deficient mice with transgenic mice carrying FAD 
mutations will reveal whether AD-relevant synaptic and behav-
ioral deficits can be rescued by PrP deficiency in vivo. Another 
intriguing question is whether Aβ42-PrP signaling is important 
for synaptic pruning during normal development given that APP, 
APP-processing enzymes, and PrP are expressed in a spatial and 
temporal manner that parallels this process. Interestingly, a spe-
cific polymorphism in PrP appears to reduce the risk of develop-
ing AD (Bertram and Tanzi, 2008). Might this polymorphism affect 
PrP’s interaction with Aβ42?
N-APP and DR6 in Development
In their new study, Nikolaev et al. (2009) uncover a physiological 
function for the APP-processing product N-APP in developmen-
tal pruning and culling of neurons. Their study suggests an alter-
native, although mutually compatible, view of AD pathogenesis. 
Although progressive neuronal loss and neurite degeneration are 
key features of AD and other neurodegenerative disorders, the 
fact that neuronal and neurite loss occurs normally in the devel-
oping brain is often overlooked. Excess neurons are born dur-
ing development of the nervous system, and 50% or more are 
subsequently eliminated in a manner dependent on neurotrophic 
support (or lack thereof) (Raff et al., 1993). Similarly, the forma-
tion of axons during development is generally exuberant, but then 
axons undergo trophic factor-dependent pruning to achieve pre-
cise neural connectivity (Luo and O’Leary, 2005). The process of 
excessive connectivity followed by trophic factor-based selection 
and elimination is thought to ensure the robust yet specific forma-
tion of proper connections and circuitry in the CNS. Depending 
on the specific context, there may be small-scale axonal prun-
ing, large-scale axonal pruning, or death of the entire neuron. The 
molecular mechanisms underlying this culling process are under 
investigation, but Trk receptors, the p75 neurotrophin receptor, 
and components of the death receptor pathways are emerging as 
important players (Luo and O’Leary, 2005).
It is not clear whether, or to what extent, pruning of axons and 
culling of neurons takes place in AD. Thus far, axonal transport 
defects, distended axons, and axonal dystrophy have been 
reported in AD brain tissue rather than the large-scale axon elimi-
nation seen in developmental pruning. Similarly, it is unclear how 
much of a role the extrinsic apoptosis pathway plays in AD, given 
that contributions from different types of neuronal loss (necrotic, 
apoptotic, necroptotic) are still under debate (Ellis et al., 1991).
On the other hand, some of the signaling components involved 
in developmental pruning/culling appear to be activated during 
AD. For example, altered expression of neurotrophins and their 
receptors has been reported (Schindowski et al., 2008), and neu-
rotrophic factors have been administered in mouse models and 
clinical trials to delay neurodegeneration (Tuszynski et al., 2005), suggesting that trophic support-dependent survival or elimination 
mechanisms may be at work in AD. Interestingly, mice overex-
pressing an antibody against nerve growth factor exhibit AD-like 
features, including plaques and tangles (Capsoni et al., 2000). 
Other pruning/culling components implicated in AD pathogen-
esis include the Fas death receptor (CD95), TNF receptors, and 
the p75 receptor. However, as these signaling pathways are also 
upregulated in response to neuronal injury, it is uncertain whether 
these components contribute to primary causative mechanisms 
or reflect secondary processes such as neuroinflammation.
Shedding new light on the matter, Nikolaev and colleagues 
reveal a physiological mechanism in which an APP product 
(N-APP) binds directly to a death receptor to trigger axonal prun-
ing and neuronal culling during development. These processes 
are thought to be activated by a lack of trophic factors, so depriv-
ing primary embryonic neurons of trophic factors is a popular 
system for examining the culling of neurons and axons. Using this 
system and genetic mouse models, the authors determined that 
DR6 is required for the timely pruning of axons and the elimina-
tion of neurons during spinal cord or retinal development in vivo 
and in trophic factor-deprived neuronal cultures. DR6-dependent 
axonal pruning is mediated by caspase 6 and neuronal culling by 
caspase 3. Trophic factor deprivation induced cleavage of APP 
by β-secretase, resulting in formation of sAPPβ and subsequently 
N-APP. Surprisingly, N-APP acts as a necessary and sufficient 
ligand for DR6, inducing axonal and neuronal degeneration after 
trophic factor removal. However, neither inhibition of α-secretase 
nor antibody-mediated blocking of Aβ42 affected this pathway, 
although Aβ42 did trigger axonal degeneration in a DR6-indepen-
dent manner. An oversprouting axon phenotype similar to that 
in mice lacking DR6 was seen in mice lacking both APP and a 
closely related protein, APLP2, further supporting a role in prun-
ing. Collectively, the authors demonstrate a new signaling mod-
ule involving N-APP and DR6 that is activated by the β-secretase 
BACE1, and that triggers the degeneration of axons and neurons 
lacking sufficient trophic support.
How does this mechanism fit with our current view of AD patho-
genesis? The finding that N-APP rather than Aβ42 binds to DR6 
implicates a new nonamyloid APP product in AD. On the other 
hand, roles for N-APP and Aβ42 in AD are not necessarily exclu-
sive, and may even work in conjunction. Aβ42 may mediate sup-
pression of LTP, whereas N-APP may induce axonal degeneration 
and neuronal loss. Although Aβ42 does not act as a DR6 ligand, 
inhibitors of γ-secretase partly block trophic deprivation-induced 
axonal degeneration, raising the possibility that γ-secretase activ-
ity somehow feeds into this signaling mechanism. Further exami-
nation of the relationships between these two divergent branches 
of APP processing is warranted. There are also questions about 
the formation of the mysterious N-APP fragment, which appears 
to be sufficient to induce trophic deprivation-induced degen-
eration of neurons. Trophic factor deprivation strongly induced 
N-APP formation in a β-secretase-dependent manner. What 
mechanisms during trophic deprivation-induced pruning could 
result in the dramatic and specific induction of β-secretase activ-
ity? Once sAPP species are made, what cleaves sAPP to gener-
ate the N-APP ligand? Is this cleavage an obligatory step? Finally, 
are N-APP levels increased in AD brain tissue, and, if so, at which 
stage of the disease?Cell 137, June 12, 2009 ©2009 Elsevier Inc. 999
This study may also provide tools to examine a critical unre-
solved question in AD: what determines susceptibility? A central 
mystery is the age-dependent nature of AD and that certain brain 
regions are more susceptible than others. Could region-specific 
or age-dependent expression of N-APP or DR6, or trophic factor 
availability, determine susceptibility to AD? Do risk factors associ-
ated with AD, such as prior brain injury or stroke, lead to upregu-
lation of N-APP or DR6? Transgenic mice overexpressing APP 
carrying FAD mutations (which may have high levels of N-APP) 
display synaptic dysfunction but not overt neurodegeneration. 
What permissive environment is required to trigger neurodegen-
eration in these mice? The authors report that trophic factors can 
act both upstream and downstream of N-APP-DR6 signaling; as 
downstream components, they provide a “fail-safe” mechanism 
to prevent degeneration even in the presence of N-APP and DR6. 
Could trophic factor availability determine susceptibility to AD in 
a manner analogous to the competitive survival of neurons dur-
ing development? The Nikolaev et al. findings provide substance 
to the intriguing idea that AD may be a disease of the aberrant 
deployment of pruning and culling mechanisms that operate dur-
ing development. This study provides specific molecules and sig-
naling events that can be investigated in future studies and pin-
points DR6, caspase 6, and the sAPPβ-to-N-APP cleavage event 
as potential therapeutic targets.
APP in Physiology and Pathology
Early observations of amyloid plaques (and neurofibrillary tan-
gles) as defining features of AD pathology, and the subsequent 
characterization of fibrillar amyloid deposits in plaques, has led 
to the view that AD is an “amyloidopathy” and a disease of pro-
tein misfolding and aggregation. This perspective emphasizes a 
toxic gain-of-function mechanism based on the propensity of Aβ 
to form insoluble fibrils that is unrelated to a physiological role for 
Aβ or other APP products. Lately, it has been suggested that the 
extensive fibrillar aggregates found in amyloid plaques may not 
be directly related to AD etiology, and that early-stage Aβ aggre-
gates, such as oligomers, may be more relevant to pathogenesis. 
Also, APP and its products are increasingly recognized as playing 
important physiological roles in the brain. Might the underlying 
causes of AD be more related to the physiological roles of Aβ and 
other APP products than previously appreciated?
APP may have a range of physiological functions associated 
with developing and adult neurons that are modulated through its 
sequential processing pathways and mediated through specific 
interactions with cell-surface proteins (for secreted species) and 
intracellular proteins (for AICD) (Figure 1). This scheme is complex, 
depending not only on modulation of enzyme expression and 
activity but also on the intricate modulation of substrate-enzyme 
interactions. For example, it remains to be determined whether 
trophic deprivation induces shedding of surface APP through 
upregulation of BACE1, altered distribution of APP or BACE1 in 
the endocytosis pathway, or a combination of multiple factors.
In AD, it is clear that this complex network of APP processing-
based signaling is altered and hyperactivated. This could stem 
from genetic factors such as APP mutations or from sporadic 
factors. Accumulation of APP products, in particular Aβ42 and 
N-APP, may trigger synaptic suppression and neurodegenera-
tion, resulting in AD pathogenesis. Importantly, these actions of 1000 Cell 137, June 12, 2009 ©2009 Elsevier Inc.Aβ42 and N-APP may depend on the expression and accessibility 
of their receptors, PrP and DR6, respectively, and of downstream 
components, a prerequisite that may underlie the age-dependent 
and brain region-dependent susceptibility of AD. A critical, unan-
swered question is why and how APP processing is upregulated 
in sporadic AD. Perhaps important insights may be gleaned from 
the induction of β-secretase activity by trophic factor deprivation, 
as Nikolaev and coworkers observed. 
These ideas, of course, are speculative, but nonetheless the 
findings of the two new studies should goad us to reconsider how 
we view AD. They suggest that distinct “suppressive” or “degen-
erative” roles for APP products that normally serve a useful func-
tion could cause AD when ectopically or excessively activated in 
the aged human brain. It is cautiously anticipated that subsequent 
studies will fill in the necessary gaps and complete the bridge 
between the physiology and pathology of AD, and with it a blue-
print for a cure.
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